Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

NCT04492501 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Covid19
Cytokine Release Syndrome
Critical Illness
ARDS

Interventions

PROCEDURE: Therapeutic Plasma exchange
BIOLOGICAL: Convalescent Plasma
DRUG: Tocilizumab
DRUG: Remdesivir
BIOLOGICAL: Mesenchymal stem cell therapy

Sponsor

UNICEF

Collaborators

[object Object]